Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E18.36 EPS (ttm)19.54 Insider Own0.10% Shs Outstand211.40M Perf Week2.94%
Market Cap75.83B Forward P/E13.53 EPS next Y26.51 Insider Trans26.89% Shs Float210.21M Perf Month20.83%
Income4.14B PEG2.66 EPS next Q5.28 Inst Own90.80% Short Float2.04% Perf Quarter36.38%
Sales12.59B P/S6.02 EPS this Y3.00% Inst Trans0.21% Short Ratio2.31 Perf Half Y4.76%
Book/sh66.48 P/B5.40 EPS next Y10.25% ROA12.50% Target Price363.35 Perf Year27.46%
Cash/sh27.98 P/C12.82 EPS next 5Y6.91% ROE23.20% 52W Range249.17 - 370.57 Perf YTD12.60%
Dividend- P/FCF16.24 EPS past 5Y24.80% ROI21.90% 52W High-3.20% Beta0.90
Dividend %- Quick Ratio3.00 Sales past 5Y17.30% Gross Margin86.60% 52W Low43.96% ATR8.91
Employees7300 Current Ratio3.20 Sales Q/Q11.40% Oper. Margin46.50% RSI (14)77.26 Volatility1.61% 2.18%
OptionableYes Debt/Eq0.42 EPS Q/Q60.00% Profit Margin23.50% Rel Volume0.89 Prev Close358.11
ShortableYes LT Debt/Eq0.42 EarningsJul 24 BMO Payout0.00% Avg Volume1.85M Price358.71
Recom2.00 SMA2011.16% SMA5018.09% SMA20017.16% Volume1,648,107 Change0.17%
Jul-10-18Downgrade Robert W. Baird Outperform → Neutral
Jul-06-18Upgrade Citigroup Neutral → Buy
May-31-18Upgrade Canaccord Genuity Hold → Buy $350 → $335
Apr-25-18Upgrade Robert W. Baird Neutral → Outperform
Apr-05-18Downgrade Barclays Overweight → Equal Weight $395 → $295
Feb-16-18Downgrade Argus Buy → Hold
Feb-05-18Reiterated Mizuho Buy $400 → $433
Jan-26-18Reiterated H.C. Wainwright Buy $340 → $363
Jan-24-18Reiterated Canaccord Genuity Hold $340 → $350
Jan-17-18Reiterated Canaccord Genuity Hold $340 → $350
Dec-22-17Reiterated Nomura Buy $355 → $420
Dec-20-17Upgrade Credit Suisse Neutral → Outperform
Oct-27-17Initiated Canaccord Genuity Hold $340
Oct-25-17Reiterated RBC Capital Mkts Sector Perform $315 → $313
Oct-24-17Initiated Guggenheim Buy $402
Oct-23-17Resumed Piper Jaffray Overweight $390
Oct-23-17Downgrade Citigroup Buy → Neutral
Oct-17-17Upgrade Stifel Hold → Buy $300 → $415
Oct-17-17Upgrade Mizuho Neutral → Buy $319 → $400
Oct-05-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-20-18 08:39AM  Biogen to Host Investor Webcast to Discuss Alzheimers Disease Portfolio on July 25, 2018 GlobeNewswire
08:35AM  Prepare for Volatility Around Biogen Ahead of Alzheimer's Presentation: Leerink TheStreet.com
07:30AM  Jim Cramer Advises His Viewers On BlackRock, Target And More Benzinga
07:00AM  Wired News Biogen to Present Data from Alzheimers Disease Clinical Development Portfolio at AAIC in Chicago ACCESSWIRE
Jul-19-18 02:04PM  Here's Why AC Immune SA Rose as Much as 21.6% Today Motley Fool
09:45AM  Biogen (BIIB) to Report Q2 Earnings: What's in the Cards? Zacks
08:48AM  Delivering Alpha 2018: Everything You Need To Know Benzinga
08:00AM  Trending: Disillusioned Investors Punish Netflix Stock Due to Subscriber Shortfall ETF Database
Jul-18-18 09:12PM  New Drugs and Expected Growth Could Trigger a Recovery for Celgene Stock InvestorPlace
05:30PM  Final Trade: BIIB, TTWO & more CNBC Videos
03:07PM  5 Big Biotech Stories to Watch TheStreet.com
03:06PM  Biogen is Sarissa's Alex Denner's best idea at Delivering... CNBC Videos
03:04PM  Hedge fund manager and Icahn protege is bullish on three drug stocks including Biogen CNBC
07:31AM  Data to be Presented From Biogen's Alzheimer's Disease Clinical Development Portfolio at the 2018 Alzheimer's Association International Conference (AAIC) GlobeNewswire
Jul-16-18 07:55AM  The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon Zacks
Jul-15-18 08:00AM  Better Buy: Biogen Inc. vs. Amgen Motley Fool
Jul-13-18 02:20PM  Are We on the Cusp of a Big Alzheimer's Disease Breakthrough? Motley Fool
10:54AM  Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom Zacks
09:47AM  5 Big Pharma Stocks Investors Love Right Now InvestorPlace
Jul-12-18 11:50PM  Dopamine and the Weather, Part 2 Zacks
10:11AM  3 Real Risks That Could Make You Reconsider Buying Celgene Stock InvestorPlace
08:46AM  Is Ionis Pharmaceuticals, Inc. a Buy? Motley Fool
05:17AM  South Korea regulator says Samsung BioLogics violated accounting rules Reuters
Jul-11-18 09:41AM  Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More Zacks
Jul-10-18 05:10PM  Why Alphabet, Cerner, and Biogen Slumped Today Motley Fool
11:54AM  Analyst downgrades Biogen after positive market reaction ... CNBC Videos
09:15AM  Biogen Is the Right Alzheimers Stock At the Wrong Time InvestorPlace
06:31AM  Do Surprising Alzheimer's Disease Results Make Biogen Stock a Smart Buy Now? Motley Fool
Jul-09-18 02:30PM  How To Trade: Why Biogen Fell Below Its Buy Point On Breakout Day, But Still Won Big Investor's Business Daily
10:35AM  Biotech ETFs Surge on Biogen's Positive Drug Trial Result Zacks
10:02AM  Stock Market News For Jul 9, 2018 Zacks
09:43AM  Biogen Stock: A Long-Term Bullish Perspective TheStreet.com
08:00AM  Today's Research Reports on Stocks to Watch: Biogen and Amgen ACCESSWIRE
07:00AM  Biogen Scores Surprise Win Morningstar
Jul-08-18 03:54PM  5 Top Stock Trades for Monday InvestorPlace
09:37AM  Biogen stock surges 16% as analysts mostly cheer positive results in Alzheimers trial MarketWatch
Jul-07-18 11:17AM  Biogen Sparks Hope on Treating Alzheimer's Disease: Everything You Must Know TheStreet.com
08:18AM  Biogen Alzheimer's drug success: A big step because almost everything that came before it has failed CNBC
07:15AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
12:01AM  [$$] Biogen's Bump Good for Biotech Barrons.com
Jul-06-18 08:08PM  Drugmakers Call Experimental Alzheimers Drug Study Positive The Wall Street Journal +19.63%
08:08PM  [$$] Dont Chase Biogen Into the Unknown on Alzheimers The Wall Street Journal
08:00PM  Stocks Rise Despite Trade War Worries; Biogen Shares Soar -- ICYMI TheStreet.com
07:01PM  After the Bell: Dow Gains 99.74 Points Because 100 Was Too Much to Ask Barrons.com
06:47PM  Drugmakers Call Experimental Alzheimer's Drug Study Positive The Wall Street Journal
05:29PM  Is health care the ultimate hideout trade? CNBC Videos
05:28PM  Video: Jim Cramer on the Jobs Report, Tariffs and Biogen TheStreet.com
05:22PM  Biogen, Eisai Aim to Bring Their Alzheimer Drug to Market TheStreet.com
05:06PM  Alzheimer's Research Gets Glimmer of Hope, Not for First Time Bloomberg
04:54PM  What Happened in the Stock Market Today Motley Fool
04:38PM  [$$] Don't Chase Biogen Into the Unknown on Alzheimer's The Wall Street Journal
04:37PM  Biogen, Microsoft gain; PriceSmart, Silicon Motion fall Associated Press
04:31PM  Biogen Soars as Surprise Alzheimer's Trial Results Fuel Hope Bloomberg Video
04:31PM  Biogen Soars as Surprise Alzheimer's Trial Results Fuel Hope Bloomberg
04:20PM  Biogen Stock Flirts With Breakout On Alzheimer's Treatment Furor Investor's Business Daily
04:15PM  Biogen chairman: Alzheimers trial extremely encouraging but we need to do a lot more CNBC
04:14PM  Biogen Wins a Battle, Not the War Against Alzheimer's TheStreet.com
04:11PM  Why Hope Endures For An Alzheimer's Treatment And Biogen Could Be First Investor's Business Daily
04:10PM  Jobs Report Drives Stocks to Second Day of Gains TheStreet.com
03:35PM  Stitch Fix Breaks Out, FAANG Stocks Rally In Broad Market Advance Investor's Business Daily
03:32PM  Biogen soars on promising results from Alzheimer's drug t... CNBC Videos
03:13PM  Why Biotech Stocks Rallied on Biogen's Alzheimer's Test Zacks
03:00PM  3 Must Reads on the Market From TheStreet's Top Columnists TheStreet.com
02:49PM  Index Funds: This Sector Races Ahead As Top Stock Biogen Soars Investor's Business Daily
02:44PM  Alzheimer's drug will lead to some societal decisions: An... CNBC Videos
02:41PM  I'm cautiously optimistic about this Alzheimer's trial: S... CNBC Videos
01:50PM  Biotech ETFs Climb on Biogens Promising Clinical Trial ETF Trends
01:49PM  The Biogen Bump Bodes Well for Biotech Barrons.com
01:37PM  An Alzheimers drug thought to be a failure may work after all Quartz
01:31PM  Citi upgrades Biogen to "buy" and raises price target to ... CNBC Videos
01:27PM  After Biogen's Alzheimer's Update, Wall Street Reacts Benzinga
12:57PM  Tesla factory under investigation; Biogen soars; bearish call on Square; Alibaba price target lowered Yahoo Finance Video
12:45PM  Why Biogen Inc. Stock Soared 15.2% Today Motley Fool
12:26PM  Biotech Stocks Rally on Biogen's Landmark Test TheStreet.com
11:54AM  Dont Buy Biogen Stock on the Promise of an Alzheimers Breakthrough InvestorPlace
11:47AM  Biogen: Let the Situation Cool Off a Bit Before Buying TheStreet.com
11:43AM  Biogen Inc Stock Shoots Higher on Alzheimers Drug Trial InvestorPlace
11:40AM  An Epidemic on Wall Street The Wall Street Journal
10:31AM  How Does Biogen Make its Money? Investopedia
10:26AM  Biogen soars on Alzheimer's drug trial, JPM denies Deutsche Bank interest, Facebook in talks with Ronaldo Yahoo Finance Video
10:18AM  Tech Stocks Lead On Strong Jobs Report; This Biotech Stock Soars Investor's Business Daily
09:40AM  Yahoo Finance Live: Midday Movers - Jul 6th, 2018 Yahoo Finance Video
09:35AM  Biogen's Alzheimer Disease Candidate Succeeds in Phase II Zacks
09:22AM  Stocks to Watch: JPMorgan, Caterpillar, Exxon Mobil, Biogen, Wynn, PriceSmart The Wall Street Journal
09:06AM  Exposure to Feverish Biogen Should Give These 2 Biotech ETFs Booster Shots TheStreet.com
09:00AM  The Market In 5 Minutes: Biogen, Pruitt, Unemployment, Tariffs And More Benzinga
09:00AM  Biogen surges on drug trial CNBC Videos
08:56AM  Morning Movers: Dow Erases Losses as Payrolls Shine, Biogen Soars, Costco Dips Barrons.com
08:17AM  Biogen shares soar 15% on successful Alzheimer's drug trial CNBC
08:09AM  Stocks making the biggest moves premarket: NOC, LMT, SATS, F, TSLA, BIIB, BA & more CNBC
08:02AM  Benzinga's Daily Biotech Pulse: Biogen And Eisai's Alzheimer's Drug Meets End Points In Mid-Stage Trial, Obseva To List Shares On Swiss Exchange Benzinga
07:59AM  Biogen Soars, and It May Signal a Breakout Gap to Further Gains TheStreet.com
07:20AM  Yahoo Finance Live: Market Movers - Jul 6th, 2018 Yahoo Finance Video
06:28AM  Biogen shares leap as Alzheimer's drug shows potential to slow disease American City Business Journals
06:00AM  5 Bargain Biotechs Poised for Big Short-Term Gains Investopedia
02:01AM  Biogen Surges After Positive Results in Alzheimers Trial Bloomberg
12:17AM  [$$] Biogen success offers hope for Alzheimers treatment Financial Times
Jul-05-18 07:51PM  Eisai And Biogen Announce Positive Topline Results Of The Final Analysis For BAN2401 At 18 Months PR Newswire
07:32PM  Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months GlobeNewswire
07:30AM  [$$] Biogen, Eisai say Alzheimers drug succeeds in mid-stage trial Financial Times
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. The company's Phase II clinical trial products comprise Opicinumab for MS; BAN2401 for Alzheimer's disease; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild AD. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. It has strategic collaboration with Ionis Pharmaceuticals to develop drug candidates for neurological diseases. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,38405,897Jun 05 04:31 PM
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,687010,118May 04 06:09 PM
DENNER ALEXANDER JDirectorApr 25Buy269.9148,00012,955,680461,858Apr 27 07:48 AM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.0053204,539Mar 05 04:41 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 27Sale290.8325975,3256,553Feb 28 05:39 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 23Option Exercise0.0046707,020Feb 27 06:25 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 23Option Exercise0.009204,772Feb 27 06:24 PM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecFeb 23Option Exercise0.00857025,225Feb 27 06:22 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 23Sale293.44908266,4446,553Feb 27 06:25 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 22Option Exercise0.0019404,738Feb 26 04:11 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 22Option Exercise0.001,63508,188Feb 26 04:12 PM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecFeb 22Option Exercise0.001,635025,095Feb 26 04:10 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 20Sale292.00743216,9566,553Feb 21 04:10 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.005,354010,233Feb 20 04:27 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Option Exercise0.001,33909,186Feb 20 04:25 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.001,47204,854Feb 20 04:23 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 15Option Exercise0.001,71205,407Feb 20 04:20 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 15Option Exercise0.0016104,600Feb 20 04:18 PM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecFeb 15Option Exercise0.001,712023,970Feb 20 04:17 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Sale298.851,294386,7127,296Feb 20 08:09 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 12Option Exercise0.002,01208,565Feb 14 06:37 PM
PANGIA ROBERT WDirectorJan 09Option Exercise57.835,832337,26523,539Jan 10 05:28 PM
PANGIA ROBERT WDirectorJan 09Sale329.655,8321,922,51917,707Jan 10 05:28 PM
Vounatsos MichelChief Executive OfficerDec 29Buy320.55780250,0294,879Jan 02 04:21 PM
DENNER ALEXANDER JDirectorNov 29Buy319.8410,0003,198,400413,858Nov 30 07:30 AM
DENNER ALEXANDER JDirectorNov 28Buy316.1220,0006,322,400403,858Nov 30 07:30 AM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecJul 25Sale290.014,9741,442,51022,258Jul 26 04:22 PM